RT Journal Article
SR Electronic
T1 Testing-on-a-probe biosensors reveal association of early SARS-CoV-2 total antibodies and surrogate neutralizing antibodies with mortality in COVID-19 patients
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.11.19.20235044
DO 10.1101/2020.11.19.20235044
A1 Yang, He S.
A1 Racine-Brzostek, Sabrina E.
A1 Karbaschi, Mohsen
A1 Yee, Jim
A1 Dillard, Alicia
A1 Steel, Peter A.D.
A1 Lee, William T.
A1 McDonough, Kathleen A.
A1 Qiu, Yuqing
A1 Ketas, Thomas J.
A1 Francomano, Erik
A1 Klasse, P. J.
A1 Hatem, Layla
A1 Westblade, Lars
A1 Wu, Heng
A1 Chen, Haode
A1 Zuk, Robert
A1 Tan, Hong
A1 Girardin, Roxanne C.
A1 Dupuis, Alan P.
A1 Payne, Anne F.
A1 Moore, John P.
A1 Cushing, Melissa M.
A1 Chadburn, Amy
A1 Zhao, Zhen
YR 2020
UL http://medrxiv.org/content/early/2020/11/22/2020.11.19.20235044.abstract
AB The association of mortality with early humoral response to SARS-CoV-2 infection within the first few days after onset of symptoms (DAOS) has not been thoroughly investigated partly due to a lack of sufficiently sensitive antibody testing methods. Here we report two sensitive and automated testing-on-a-probe (TOP) biosensor assays for SARS-CoV-2 viral specific total antibodies (TAb) and surrogate neutralizing antibodies (SNAb), which are suitable for clinical use. The TOP assays employ an RBD-coated quartz probe using a Cy5-Streptavidin-polysacharide conjugate to improved sensitivity and minimize interference. Disposable cartridge containing pre-dispensed reagents requires no liquid manipulation or fluidics during testing. The TOP-TAb assay exhibited higher sensitivity in the 0-7 DAOS window than a widely used FDA-EUA assay. The rapid (18 min) and automated TOP-SNAb correlated well with two well-established SARS-CoV-2 virus neutralization tests. The clinical utility of the TOP assays was demonstrated by evaluating early antibody responses in 120 SARS-CoV-2 RT-PCR positive adult hospitalized patients. Higher baseline TAb and SNAb positivity rates and more robust antibody responses were seen in patients who survived COVID-19 than those who died in the hospital. Survival analysis using the Cox Proportional Hazards Model showed that patients who were TAb and SNAb negative at initial hospital presentation were at a higher risk of in-hospital mortality. Furthermore, TAb and SNAb levels at presentation were inversely associated with SARS-CoV-2 viral load based on concurrent RT-PCR testing. Overall, the sensitive and automated TAb and SNAb assays allow detection of early SARS-CoV-2 antibodies which associate with mortality.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was partially funded by a COVID-19 research grant from Weill Cornell Medicine.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The clinical study was approved by the Institutional Review Board (#20-03021671) of Weill Cornell Medicine (WCM) with a waiver of informed consent. Neutralizing antibody testing at the Wadsworth Center was done under a declared Public Health Emergency with a waiver from the NYSDOH Institutional Review Board.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data are available upon request